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Background: There are few data comparing patient-reported
outcomes (PROs) in randomized trials of initial antiretroviral
therapy. We present results from a substudy of the NEAT001/
ANRS143 trial.
Methods: The randomized trial compared ﬁrst-line DRV/r 800/100
mg once daily plus RAL 400 mg twice daily and DRV/r plus TDF/
FTC 245/200 mg once daily. Changes in PROs were assessed with 3
questionnaires: EuroQoL 5 domains (EQ-5D), Center for Epidemi-
ologic Studies Depression (CES-D) scale, and HIV Treatment
Satisfaction Questionnaire. Major depressive disorder (MDD) was
deﬁned as CES-D $ 16. General estimating equations were used to
model change over 96 weeks in PROs from baseline.
Results: Of the 805 participants, 797 (99%) contributed to the
substudy. Baseline PRO data were similar for the 2 randomized
groups. Health status improved over time with a mean increase in
EQ-5D visual analogue scale (VAS) of 8.0 by W96 [95% conﬁdence
interval (CI): 6.5 to 9.4; P , 0.001], and no statistically signiﬁcant
differences between groups (difference of 0.3 on VAS score (95%
CI: 21.7 to 2.3); P = 0.7, global P value $0.05 for all domains over
follow-up). There was no signiﬁcant difference between groups on
CES-D [difference of20.1 (95% CI:21.3 to 1.1); P = 0.9], or MDD
during follow-up, adjusted for baseline MDD (odds ratio = 0.98,
95% CI: 0.82 to 1.18; P = 0.9). RAL + DRV/r group had lower level
of convenience (P = 0.03) and ﬁtted less well into patients’ lifestyle
(P = 0.007) than the TDF/FTC + DRV/r regimen, and was associated
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with lower treatment satisfaction [median score: 53 RAL + DRV/r vs
55 TDF/FTC + DRV/r (P = 0.001)].
Conclusion: PROs improved after starting antiretroviral therapy,
with no statistically signiﬁcant difference between groups. The lower
satisfaction with RAL + DRV/r may be explained by twice-
daily administration.
Key Words: quality of life, raltegravir, treatment satisfaction, EQ-
5D, ritonavir-boosted darunavir, health improvement
(J Acquir Immune Deﬁc Syndr 2018;79:519–526)
INTRODUCTION
Antiretroviral therapy (ART) has dramatically
reduced mortality and morbidity at all stages of HIV
infection,1,2 making an overall improvement of patients’
health status an important goal of therapy. In fact,
according to most recent guidelines, one of the key
treatment goals is to “prolong the quality of survival.”3
In this context, patient-reported outcomes (PROs) have
been recognized as an important measure of health that
deserves to be taken into account, together with the
traditional efﬁcacy and safety parameters, when measuring
a patient’s health status both in research and clinical
practice. Indeed, there is compelling evidence that both
HIV infection and prolonged ART can impair PROs such
as health-related quality of life (HRQL), fatigue, and work
productivity.4 Assessment of PRO measures is of particular
interest when two or more therapeutic strategies have the
same clinical efﬁcacy because PROs are the major drivers
of adherence to long-term ART.5 In fact, PROs during
treatment may explain the gap that is frequently reported
between efﬁcacy rates and those reported for the effective-
ness of ART in the real world practices. PROs are also
important surrogates for patients’ experience with their
disease and its treatment.6 Combined, these reasons make
PROs important endpoints for clinical trials to identify the
strategy that maximize the patient’s health status and
irreplaceable sources of important information in clinical
practice.7 A large European NEAT001/ANRS143 random-
ized multicenter trial that compared 2 different ART
regimens for ﬁrst-line treatment in naive patients showed
non-inferiority based on a virological composite primary
outcome at 96 weeks. There was also no difference in the
frequency of serious or treatment-modifying adverse
events. We report the results of a speciﬁc PROs’ substudy
nested within the NEAT001/ANRS143 large clinical trial.
PARTICIPANTS AND METHODS
Study Treatment and Participants
NEAT001/ANRS143 was a randomized, open-label,
non-inferiority trial conducted in 15 European countries
between August 2010 and October 2013. The full study
design and results have been previously reported.8 Brieﬂy,
805 naive HIV-infected adults were randomly assigned in
a 1:1 ratio to receive oral treatment with 800-mg darunavir
and 100-mg ritonavir once daily plus either 400-mg
raltegravir twice daily [nucleotide reverse transcriptase
inhibitor (NtRTI)-sparing regimen) or tenofovir/emtricita-
bine in a 245- and 200-mg ﬁxed dose combination once
daily (standard regimen). Participants were offered to
participate in the PROs’ substudy. Ethics committee
approval was obtained for all participating centers, in
accordance with the principles of the Declaration of
Helsinki. All trial participants gave written informed
consent. The study was registered with ClinicalTrials.
gov (NCT01066962).
Data Collection
Participants attended study centers at screening,
baseline (randomization), weeks 2, 4, 8, 12, 18, 24, 32,
48, 64, 80, and 96, and every 12–16 weeks thereafter. Each
visit included assessment of vital signs and adverse events,
physical examination, and collection of blood samples for
full blood cell counts and serum chemistry, liver function,
and immunovirological measurements, except at W2 for
the latter. Adverse events recorded during the study were
grouped based on the body system as previously
described.8
Patient-Reported Outcomes
PROs were collected at baseline and during scheduled
follow-up visits at weeks 4, 12, 24, 48, and 96 through self-
administered questionnaires in participants’ native languages.
Four PRO questionnaires were used in this study: (1) the
EuroQoL 5 domains (EQ-5D),9 a widely used generic
questionnaire for measuring health-related quality of life
(HRQL), that includes 2 parts. The EQ-5D self-classiﬁer
asks participants to describe their health on 5 domains:
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression) and 3 levels: (1) indicating “no problem,”
(2) indicating “some or moderate problems,” and (3)
indicating “extreme problems/impossible to do.” The EQ-
VAS is a visual analogue scale (VAS) that takes values
between 100 (best imaginable health) and 0 (worst imaginable
health) on which participants provide an overall measure of
their health status; (2) the ISS-NEAT HIV symptoms scale,
a self-administered list of 38 symptoms,10 that evaluates the
impact of symptoms over the past 4 weeks through a Likert 5-
point intensity scale rated from “not at all” = 1 to “a very
great deal” = 5; (3) the Center for Epidemiologic Studies
Depression (CES-D), that asks participants to rate how often
over the past week they experienced symptoms associated
with depression, with response options ranging from 0 to 3
for each item (0 = rarely or none of the time, 1 = some or little
of the time, 2 = occasionally or moderately, and 3 = most or
all the time). Major depressive disorder (MDD) was deﬁned
as CES-D $16. In this study, a short version of 10 items was
used11; and (4) the HIV Treatment Satisfaction Questionnaire
(HIVTSQ) measuring overall satisfaction with HIV treatment
and by speciﬁc domains such as convenience, ease of use, and
ﬂexibility through a 10-item self-reported scale with a maxi-
mum possible score of 60.12
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Statistical Analyses
Together with clinicodemographic parameters, the
PROs at and during follow-up were compared between the
2 trial treatments using Pearson’s x2 test for categorical
variables or t tests and Wilcoxon rank sum tests for
continuous variables. The two treatment groups were com-
pared as randomized, according to the intention-to-treat
principle. Generalized estimating equations (GEEs) including
all participants that contributed one or more questionnaires
were used to model: change over time in PROs from baseline;
odds of MDD during the trial adjusted for baseline MDD; and
odds of having moderate or severe problems (compared with
no problems) on EQ-5D domains adjusted for baseline levels.
GEEs were used because the models can handle missing
measurements without the need for imputation and have been
shown to be a viable analysis for PROs in HIV trial data.13
Within the GEE models, potential differences between arms
and visit weeks were accounted for with interaction terms.
Sensitivity analyses were performed by imputing missing
values of PROs at each time point using multiple imputation
with chained equations (with predictive mean matching for
CES-D and EQ-VAS, and regression for HIV symptoms
scale) and then changing the imputed values to test the
assumption that the group who had missing data had
systematically worse or better outcomes.14 Baseline factors
that were associated with change in EQ-5D VAS over time
(age, sex, country of enrollment, body mass index, mode of
infection, ethnicity, HIV stage, CD4, and log10 plasma HIV
RNA) were included in the GEE model. Levels of treatment
satisfaction between groups were compared with x2 tests in
participants with questionnaires at baseline and W96 and
logistic regression for the % very satisﬁed at W96 adjusted for
baseline factors. This time point was in line with the primary
endpoint for the main trial measured once all participants had
reached W96. For this PROs’ substudy, no predetermined
FIGURE 1. A, EQ-VAS for current health over follow up; (B) CES-d scale over follow up; (C) HIV symptoms scale over follow up.
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sample size was calculated. Statistical analyses were per-
formed using Stata v14.0.
RESULTS
Baseline Characteristics and
Data Completeness
Of the 805 participants, 797 (99%) contributed to the
substudy: 683/797 (86%) at baseline, 611 (77%) at W96, and
526 (66%) at both visits. A minimum of 74% participants
contributed to PRO data at each visit and .80% contributed at
visits within the ﬁrst 12 weeks (Fig. 1A). There was no
signiﬁcant difference between randomized groups for complete-
ness of data at each visit and overall (global P value from GEE
models for missingness of CES-D scale, EQ-VAS, and HIV
symptoms scale was 0.10, 0.41, and 0.28, respectively). Baseline
characteristics and PROs of the participants contributing at
baseline were not different between treatment groups (Table 1)
and were similar to those of the 805 participants randomized to
the main NEAT001/ANRS143 trial.
PRO Measures
There were no signiﬁcant differences between random-
ized groups for any of the EQ-5D domains including VAS
over time (Table 2 and Fig. 1A). During follow-up, an
improvement of participant overall health status (EQ-VAS)
was observed in both randomized groups, with a marked
increase during the ﬁrst 24 weeks of therapy {difference from
baseline of 7.5 [95% conﬁdence interval (CI): 6.5 to 8.5]; P,
0.001}, then a plateau; however, there were no statistically
signiﬁcant differences between randomized groups at any
time point (Fig. 1A). A reduction of the HIV symptoms scale
was observed in ﬁrst 4 weeks [difference from baseline of 23
(95% CI: 24 to 22); P , 0.001] for standard regimen, with
stabilization up to W96 and no statistically signiﬁcant differ-
ences between the 2 randomized groups (Fig. 1B). Depres-
sion/anxiety as measured on the CES-D scale also improved,
as by week 4, statistically signiﬁcant improvement was
evidenced in both groups [difference of 23 (95% CI: 24 to
22); P , 0.001], with no difference between the 2 groups
(Fig. 1C). Sensitivity analyses showed that under the
assumptions that participants with missing PROs either had
systematically worse or better outcomes, there were no
signiﬁcant differences between randomized groups for EQ-
VAS, CES-D, or HIV symptoms scale (Table 1, Supplemen-
tal Digital Content http://links.lww.com/QAI/B211). There
was no evidence of a difference between groups in MDD
during the 96-week duration of the study [odds ratio (OR)
0.98, 95% CI: 0.82 to 1.18]. At W96, participants in the
NtRTI-sparing regimen reported signiﬁcantly lower median
score in treatment satisfaction than participants in the standard
regimen {53 [interquartile range (IQR) 48–58] vs 55 (IQR 50-
59); Kruskal–Wallis P = 0.001}. There were no differences
between groups on satisfaction regarding general satisfaction,
satisfaction with control and understanding of disease, side
effects, or wish to continue current treatment (Table 3).
PRO Predictors
Age (Wald test P , 0.001) and country of enrollment
(overall Wald test P = 0.05) were found to be independently
associated with change in overall health status adjusting for
the other baseline factors and baseline EQ-5D VAS. Older
age was associated with lower VAS [decrease of 20.1 (95%
CI: 20.2 to 20.05) per age year], and 2 countries were
associated with increased VAS {Hungary [n = 6, increase of
TABLE 1. Baseline Patient-Reported Outcomes and
Characteristics
Patient-Reported Outcomes RAL + DRV/r TDF/FTC + DRV/r
Median (IQR) CES-D
score; N
12 (7, 18); 328 12 (7, 19); 332
Major depressive disorder (%) 121/328 (37%) 110/332 (33%)
Median (IQR) HIV symptoms
scale; N
49 (43, 59); 331 49 (42, 59); 337
EuroQol (EQ-5D) domains
(% moderate or severe
problems)
Mobility 11/335 (3%) 11/342 (3%)
Self-care 2/335 (,1%) 5/341 (1%)
Usual activities 26/336 (8%) 26/340 (8%)
Pain/discomfort 79/335 (24%) 90/341 (26%)
Anxiety/depression 143/336 (43%) 145/340 (43%)
Median (IQR) EQ-5D
VAS; N
80 (70–90); 319 80 (70–90); 327
Baseline characteristics for
those with any baseline
PRO recorded
N = 340 N = 343
Mean (SD) age (yr) 38 (10) 39 (10)
Male (%) 299 (88%) 305 (89%)
Mean (SD) baseline CD4
(mm3)
328 (7) 315 (7)
Mean (SD) baseline HIV
RNA (log10 c/mL)
10.9 (0.08) 10.8 (0.08)
Mean (SD) body mass index
(kg/m2)
23.8 (0.2) 23.7 (0.2)
Mode of contamination*
Homosexual/bisexual sex 230 (72%) 235 (71%)
Heterosexual sex 81 (25%) 83 (25%)
Intravenous blood use 7 (2%) 10 (3%)
Blood or blood product
receipt
1 (,1%) 0 (0%)
Other 3 (1%) 4 (1%)
Ethnic origin
White 281 (83%) 284 (83%)
Black 43 (13%) 36 (11%)
Asian 6 (2%) 8 (2%)
Other 10 (3%) 15 (4%)
HIV stage
A 279 (82%) 284 (83%)
B 44 (13%) 43 (13%)
C 17 (5%) 18 (5%)
*Percentages are based only on patients with available data (RAL + DRV/r n = 318,
TDF-FTC+DRV/r n = 329); 7 patients had more than one risk factor (RAL + DRV/r n =
4, TDF–FTC+DRV/r n = 3). There was no evidence of differences in any baseline
characteristic or PRO between the randomized arms in those that had any baseline PRO
recorded.
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11 (95% CI: 1 to 21); P = 0.03] and Portugal [n = 21, increase
of 12 (95% CI: 3 to 21); P = 0.007]}. The potential baseline
predictors were also included in the models for change in
CES-D and HIV symptoms scale adjusted for their baseline
values. Age was found to be an independent predictor of
change in the model for HIV symptoms scale with older age
associated with an increased score [increase of 0.1 per age
year (95% CI: 0.03 to 0.2); P = 0.006]. Sex was found to be
an independent predictor of change in CES-D score with
female sex (including transgender male to female) associated
with an increased CES-D score [increase of 2 (95% CI: 0.1 to
4); P = 0.04].
Multivariate Analysis of
Treatment Satisfaction
A logistic regression model was ﬁtted for the proportion
of participants who responded with 5 or 6 (very satisﬁed) on
each question on the HIVTSQ at W96 adjusted for treatment
group, age at enrollment, sex, and change from baseline in the
other PRO measures (CES-D, EQ-5D VAS, and HIV
symptoms scale). The proportions of participants feeling very
satisﬁed with convenience, extent with which treatment ﬁts
into their lifestyle, and who would recommend their treatment
to a friend were higher in the standard regimen after
adjustment (Table 3).
DISCUSSION
Our data indicate that most PRO domain scores
measured with 4 different validated instruments signiﬁcantly
improved during ﬁrst-line antiretroviral treatment. Previous
studies have shown reduction of fatigue and HIV symptoms
in HIV-infected patients initiating ART,15,16 but few studies
have evaluated PROs in a randomized comparative study.
In our study, improvement of PRO scores started
shortly after the initiation of therapy and then plateaued
between 6 months and 2 years on continuous therapy,
suggesting that PROs’ beneﬁt was maximal when plasma
virologic suppression was achieved and did not increase
thereafter. For 3 of the PRO measures assessed, HRQL, HIV
symptoms scale, and CES-D, improvement was not different
between the 2 randomized groups either overall or any time
point of follow-up. These results represent additive argu-
ments to the hypothesis that PRO improvement is related to
virologic suppression achievement rather than to a speciﬁc
drug regimen. However, it is interesting to note that PRO
improvement in the 1st week after treatment initiation was
of similar magnitude in both randomized groups, although at
W4 and W24, a signiﬁcantly higher proportion of partic-
ipants achieved virologic suppression on the NtRTI regi-
men, while at 96 weeks, both regimens were virologically
noninferior.8 The underlying mechanisms to connect HIV
plasma suppression with PRO improvement are yet to be
elucidated.17 Some putative mechanisms may be related to
the improvement of cytokine and other metabolites proﬁle,
both in peripheral blood and central nervous system,
because of the viral suppression that could in turn positively
impact patients’ experience.18 Viral suppression might thus
improve fatigue and other PROs related to chronic HIV
infection.19
Our multivariate analysis showed an association
between older age and lower health-related outcomes. Poorer
PROs in older patients has been reported in many studies on
HCV treatment, including the most recent ones with highly
effective and very well-tolerated direct-acting antiviral regi-
mens.20 Older age was negatively associated with physical
Fatigue Impact Scale subscores in an observational study on
raltegravir,19 while in a review of literature, there was no
association between age and fatigue in most studies.21 HIV
disease factors, such as US Centers for Disease Control and
Prevention (CDC) stage, CD4, and plasma HIV RNA, did not
inﬂuence PRO improvement, indicating that beneﬁt of HIV
therapy on quality of life was seen whatever the baseline
immunovirological status of the patient, taking into account
that 15 patients in our study had CD4 cell counts , 200/mm3
and only 5% CDC stage C HIV infection.
Association of worsening of depression score in women
over time might be related to higher difﬁculty to cope with
HIV disease or to higher vulnerability or perceived stigma.
Most studies in an HIV-positive population have showed
a higher rate of depression in women than men;22 however,
no longitudinal study over a 2-year period has been reported.
The difference found in improved overall health status by
country, as measured by EQ-VAS, was driven by differences
in Hungary and Portugal, and could be due to the small
numbers enrolled in the trial in these countries because
modest absolute differences from baseline in small groups can
have a large impact. HIVTSQ scores for treatment conve-
nience, ﬁtting into lifestyle, and willingness to recommend to
TABLE 2. Odds Ratios of RAL + DRV/r vs TDF/FTC + DRV/r for Having Moderate or Severe Problems in the EQ-5D Domains Over
Follow-up
EQ-5D Domain
OR of RAL + DRV/r vs TDF/FTC + DRV/r (95% CI)
W4 W12 W24 W48 W96 Global, P
Mobility (n = 677) 0.77 (0.32 to 1.90) 0.52 (0.20 to 1.36) 4.18 (1.12 to 15.66) 2.19 (0.83 to 5.82) 2.41 (0.97 to 5.96) 0.05
Self-care (n = 677) 1.26 (0.15 to 10.93) 0.49 (0.13 to 1.92) 0.71 (0.05 to 9.51) 0.26 (0.03 to 2.63) 0.24 (0.02 to 2.35) 0.80
Usual activity (n = 676) 0.99 (0.47 to 2.07) 0.98 (0.45 to 2.11) 0.98 (0.43 to 2.24) 0.77 (0.35 to 1.66) 0.75 (0.33 to 1.68) 0.99
Pain or discomfort
(n = 676)
0.74 (0.48 to 1.16) 1.13 (0.72 to 1.79) 1.63 (1.01 to 2.64) 0.96 (0.60 to 1.52) 1.12 (0.69 to 1.82) 0.26
Anxiety or depression
(n = 676)
1.09 (0.72 to 1.67) 1.14 (0.74 to 1.74) 0.87 (0.57 to 1.34) 1.10 (0.71 to 1.69) 1.33 (0.84 to 2.10) 0.85
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a friend were signiﬁcantly higher in participants taking the 3-
pill once-daily DRV/r + TDF/FTC regimen compared with 4-
pill DRV/r + RAL regimen requiring twice-daily intake,
possibly reﬂecting a preference for a simpliﬁed regimens with
less daily intake. A meta-analysis of randomized clinical trials
has shown that lower pill burden was associated with both
better adherence and virological suppression.23 However,
once-daily regimens were associated with slightly better
adherence, but not virological suppression, as compared with
twice-daily regimens.23 Absence of differences in satisfaction
with regards to side effects and HIV disease control and
knowledge between randomized groups is in line with
ﬁndings of the study showing non-inferiority of virological
efﬁcacy and no differences in safety over follow-up.8 In fact,
even if participants were less satisﬁed with twice-daily
regimens and less prone to recommend such a regimen, this
did not translate in poorer outcome at W96. Indeed, the
ﬁnding of a 2-point difference in treatment satisfaction score,
although statistically signiﬁcant, did not seem to have much
clinical relevance because it did not seem to be associated
with any adverse patient-reported or clinical outcomes.
Furthermore, participants on twice-daily DRV/r + RAL
regimen were equally satisﬁed to continue on their current
regimen than those on once-daily DRV/r + TDF/FTC,
probably because of perceived beneﬁt in terms of virologic
suppression and immunologic recovery.
The study limitations primarily arise from the nature of
any clinical trial study that has strict enrollment criteria and
close follow-up. In this context, the ﬁndings from an efﬁcacy
trial may potentially have limited generalizability to the entire
HIV population. However, the design of our study was
pragmatic with a wide range of enrollment criteria and similar
follow-up to routine care. In addition, some parameters that
could potentially be associated with PROs were not collected
during the study. These include level of education, marital
status, income, and type of work. Finally, some of the PRO
instruments were not systematically validated in all languages
used in this study. Nevertheless, all these instruments have
been systematically translated with some face-to-face and
content validation. We also acknowledge that EQ-5D might
TABLE 3. Odds Ratios of RAL + DRV/r vs TDF/FTC + DRV/r for Proportion With a “Very Satisfied” Response on the HIVTSQ at W96
and Impact of Adjusting for Potential Confounders by Logistic Regression
Treatment Satisfaction
Question at W96 [% Very
Satisﬁed (5 or 6)] RAL + DRV/r
TDF/FTC +
DRV/r
Unadjusted OR
(95% CI) for RAL vs
TDF/FTC Adjusted OR*
Other Signiﬁcant Factors in Model
[OR (95% CI)]
Satisﬁed with current
treatment
238/268 (89%) 269/288 (93%) 1.78 (0.98 to 3.25);
P = 0.06
1.55 (0.75 to 3.19);
P = 0.24
Age [1.03 (95% CI: 1.0 to 1.08)]
Satisfaction with how well
HIV was controlled
250/268 (93%) 277/287 (97%) 1.99 (0.90 to 4.40);
P = 0.09
1.99 (0.77 to 5.18);
P = 0.16
HIV symptoms scale change from
baseline [0.92 (95% CI 0.89 to
0.96)] and EQ-5D VAS change
from baseline [1.03 (95% CI 1.00
to 1.06)]
Satisﬁed with extent of
unwanted side effects
234/267 (88%) 250/287 (87%) 0.95 (0.58 to 1.57);
P = 0.85
0.88 (0.48 to 1.60);
P = 0.67
HIV symptoms scale change from
baseline [0.96 (95% CI: 0.94 to
0.99)]
Satisfaction with how
demanding treatment is
180/267 (67%) 220/286 (77%) 1.61 (1.11 to 2.34);
P = 0.01
1.43 (0.91 to 2.24);
P = 0.12
HIV symptoms scale change from
baseline [0.98 (95% CI: 0.95 to
1.00)], age [1.03 (95% CI: 1.00 to
1.05)], and sex [2.72 (95% CI: 1.03
to 7.18)]
Convenience 209/268 (78%) 249/287 (87%) 1.84 (1.18 to 2.89);
P = 0.007
1.86 (0.08 to 3.23);
P = 0.03
HIV symptoms scale change from
baseline [0.96 (95% CI: 0.94 to
0.99)]
Flexibility of treatment 176/271 (65%) 217/285 (76%) 1.72 (1.19 to 2.49);
P = 0.004
1.54 (0.99 to 2.38);
P = 0.06
CES-D score change from baseline
[0.96 (95% CI: 0.93 to 0.98)], age
[1.02 (95% CI: 1.00 to 1.05)], sex
[3.44 (95% CI: 1.30 to 9.10)]
Satisfaction with
understanding of HIV
232/266 (87%) 252/287 (88%) 1.05 (0.64 to 1.74);
P = 0.84
1.08 (0.60 to 1.94);
P = 0.78
Extent with which treatment
ﬁts into lifestyle
203/264 (77%) 250/287 (87%) 2.03 (1.29 to 3.17);
P = 0.002
2.12 (1.22 to 3.66);
P = 0.007
Recommendation to a friend 230/266 (86%) 267/288 (93%) 1.99 (1.13, 3.51);
P = 0.02
2.21 (1.09 to 4.51);
P = 0.03
Continuation of treatment 230/266 (86%) 252/286 (88%) 1.16 (0.70 to 1.92);
P = 0.56
1.43 (0.77 to 2.63);
P = 0.26
EQ-5D VAS scale change from
baseline [0.97 (95% CI: 0.95 to
0.99)] and CES-D change from
baseline [0.95 (95% CI: 0.91 to
0.99)].
*Adjusted for change from baseline in CES-D, HIV symptoms scale, and EQ-5D VAS and baseline factors: age (yr) and sex (transgender male to female = female, ORs estimated
for female vs male).
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lack sensitivity and may not capture subtle differences in
participants’ quality of life.
In summary, this randomized-controlled trial of
twice-daily DRV/r + RAL vs once-daily DRV/r + TDF/
FTC demonstrated signiﬁcant and persistent improvement
of PRO scores during treatment. PROs improve rapidly
after treatment initiation, with no difference between arms,
reﬂecting probable improvement in immunovirologic status
and/or suggestive perception of disease control while on
therapy. However, treatment satisfaction was signiﬁcantly
lower with the twice-daily regimen for convenience and
ﬁtting into the participants’ lifestyles, without affecting
W96 outcome. These ﬁndings provide a comprehensive
approach when treating and selecting initial ART in HIV-
infected participants.
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